{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:06Z","timestamp":1786980186977,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00428-026-04425-1","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:53:54Z","timestamp":1770188034000},"page":"533-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-Null to HER2-low, including HER2-ultralow status"],"prefix":"10.1007","volume":"488","author":[{"given":"Florence","family":"Boissi\u00e8re-Michot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Gudin-De-Vallerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Th\u00e9zenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Lopez-Crapez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelique","family":"Bobrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Maran-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"4425_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T et al (2022) Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"4425_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R et al (2024) Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2407086","journal-title":"N Engl J Med"},{"key":"4425_CR3","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38:1951\u20131962. https:\/\/doi.org\/10.1200\/JCO.19.02488","journal-title":"J Clin Oncol"},{"key":"4425_CR4","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. JCO 36:2105\u20132122. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738","journal-title":"JCO"},{"key":"4425_CR5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"4425_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507371","volume":"15","author":"F Boissi\u00e8re-Michot","year":"2024","unstructured":"Boissi\u00e8re-Michot F, Chateau M-C, Th\u00e9zenas S et al (2024) Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features. Front Immunol 15:1507371. https:\/\/doi.org\/10.3389\/fimmu.2024.1507371","journal-title":"Front Immunol"},{"key":"4425_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-018-0142-6","volume":"119","author":"S Guiu","year":"2018","unstructured":"Guiu S, Mollevi C, Charon-Barra C et al (2018) Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Br J Cancer 119:76\u201379. https:\/\/doi.org\/10.1038\/s41416-018-0142-6","journal-title":"Br J Cancer"},{"key":"4425_CR8","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.3390\/cancers14194829","volume":"14","author":"A Bobrie","year":"2022","unstructured":"Bobrie A, Massol O, Ramos J et al (2022) Association of CD206 protein expression with immune infiltration and prognosis in patients with triple-negative breast cancer. Cancers (Basel) 14:4829. https:\/\/doi.org\/10.3390\/cancers14194829","journal-title":"Cancers (Basel)"},{"key":"4425_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/cancers13040765","volume":"13","author":"F Boissi\u00e8re-Michot","year":"2021","unstructured":"Boissi\u00e8re-Michot F, Chabab G, Mollevi C et al (2021) Clinicopathological correlates of \u03b3\u03b4 T cell infiltration in triple-negative breast cancer. Cancers (Basel) 13:765. https:\/\/doi.org\/10.3390\/cancers13040765","journal-title":"Cancers (Basel)"},{"key":"4425_CR10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/cancers12040828","volume":"12","author":"W Jacot","year":"2020","unstructured":"Jacot W, Lopez-Crapez E, Mollevi C et al (2020) BRCA1 promoter hypermethylation is associated with good prognosis and chemosensitivity in triple-negative breast cancer. Cancers (Basel) 12:828. https:\/\/doi.org\/10.3390\/cancers12040828","journal-title":"Cancers (Basel)"},{"key":"4425_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1977-3","volume":"15","author":"W Jacot","year":"2015","unstructured":"Jacot W, Mollevi C, Fina F et al (2015) High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. BMC Cancer 15:986. https:\/\/doi.org\/10.1186\/s12885-015-1977-3","journal-title":"BMC Cancer"},{"key":"4425_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF et al (2023) ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 34:645\u2013659. https:\/\/doi.org\/10.1016\/j.annonc.2023.05.008","journal-title":"Ann Oncol"},{"key":"4425_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol 26:259\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"key":"4425_CR14","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K et al (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22:5097\u20135108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822","journal-title":"Clin Cancer Res"},{"key":"4425_CR15","doi-asserted-by":"publisher","unstructured":"Popovi\u0107 M, Silovski T, Kri\u017ei\u0107 M, Dedi\u0107 Plaveti\u0107 N (2023) HER2 low breast cancer: a new subtype or a trojan for cytotoxic drug delivery?. Int J Mol Sci 24(9):8206. https:\/\/doi.org\/10.3390\/ijms24098206","DOI":"10.3390\/ijms24098206"},{"key":"4425_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M et al (2016) Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107:1039\u20131046. https:\/\/doi.org\/10.1111\/cas.12966","journal-title":"Cancer Sci"},{"key":"4425_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.834651","volume":"9","author":"K Venetis","year":"2022","unstructured":"Venetis K, Crimini E, Sajjadi E et al (2022) HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci 9:834651. https:\/\/doi.org\/10.3389\/fmolb.2022.834651","journal-title":"Front Mol Biosci"},{"key":"4425_CR18","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.3390\/cancers13236059","volume":"13","author":"W Jacot","year":"2021","unstructured":"Jacot W, Maran-Gonzalez A, Massol O et al (2021) Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers. Cancers (Basel) 13:6059. https:\/\/doi.org\/10.3390\/cancers13236059","journal-title":"Cancers (Basel)"},{"key":"4425_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10549-023-07079-8","volume":"202","author":"Z Chen","year":"2023","unstructured":"Chen Z, Jia H, Zhang H et al (2023) Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat 202:313\u2013323. https:\/\/doi.org\/10.1007\/s10549-023-07079-8","journal-title":"Breast Cancer Res Treat"},{"key":"4425_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67795-z","volume":"14","author":"Z Shi","year":"2024","unstructured":"Shi Z, Liu Y, Fang X et al (2024) Efficacy and prognosis of HER2-low and HER2-zero in triple-negative breast cancer after neoadjuvant chemotherapy. Sci Rep 14:16899. https:\/\/doi.org\/10.1038\/s41598-024-67795-z","journal-title":"Sci Rep"},{"key":"4425_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.2021.39.15_suppl.1021","volume":"39","author":"M Scott","year":"2021","unstructured":"Scott M, Vandenberghe ME, Scorer P et al (2021) Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2\/neu (4B5) assay. JCO 39:1021\u20131021. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.1021","journal-title":"JCO"},{"key":"4425_CR22","doi-asserted-by":"publisher","unstructured":"Hu Y, Jones D, Zhao W et al (2025) Incidence, clinicopathological features and follow-up results of HER2-ultralow breast carcinoma. Mod Pathol 100783. https:\/\/doi.org\/10.1016\/j.modpat.2025.100783","DOI":"10.1016\/j.modpat.2025.100783"},{"key":"4425_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00343-4","volume":"7","author":"F Miglietta","year":"2021","unstructured":"Miglietta F, Griguolo G, Bottosso M et al (2021) Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 7:137. https:\/\/doi.org\/10.1038\/s41523-021-00343-4","journal-title":"NPJ Breast Cancer"},{"key":"4425_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F et al (2021) Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7:1. https:\/\/doi.org\/10.1038\/s41523-020-00208-2","journal-title":"NPJ Breast Cancer"},{"key":"4425_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","volume":"8","author":"AI Fernandez","year":"2022","unstructured":"Fernandez AI, Liu M, Bellizzi A et al (2022) Examination of Low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 8:1\u20134. https:\/\/doi.org\/10.1001\/jamaoncol.2021.7239","journal-title":"JAMA Oncol"},{"key":"4425_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","volume":"159","author":"C Karakas","year":"2023","unstructured":"Karakas C, Tyburski H, Turner BM et al (2023) Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort. Am J Clin Pathol 159:484\u2013491. https:\/\/doi.org\/10.1093\/ajcp\/aqac184","journal-title":"Am J Clin Pathol"},{"key":"4425_CR27","doi-asserted-by":"publisher","first-page":"882","DOI":"10.20517\/cdr.2022.29","volume":"5","author":"E Sajjadi","year":"2022","unstructured":"Sajjadi E, Venetis K, Ivanova M, Fusco N (2022) Improving HER2 testing reproducibility in HER2-low breast cancer. Cancer Drug Resist 5:882\u2013888. https:\/\/doi.org\/10.20517\/cdr.2022.29","journal-title":"Cancer Drug Resist"},{"key":"4425_CR28","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2024-0052-OA","author":"J R\u00fcschoff","year":"2024","unstructured":"R\u00fcschoff J, Penner A, Ellis IO et al (2024) Global study on the accuracy of human epidermal growth factor receptor 2-low diagnosis in breast cancer. Arch Pathol Lab Med. https:\/\/doi.org\/10.5858\/arpa.2024-0052-OA","journal-title":"Arch Pathol Lab Med"},{"key":"4425_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155472","volume":"260","author":"S Wu","year":"2024","unstructured":"Wu S, Li X, Miao J et al (2024) Artificial intelligence for assisted HER2 immunohistochemistry evaluation of breast cancer: a systematic review and meta-analysis. Pathol Res Pract 260:155472. https:\/\/doi.org\/10.1016\/j.prp.2024.155472","journal-title":"Pathol Res Pract"},{"key":"4425_CR30","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/his.14877","volume":"82","author":"M Sode","year":"2023","unstructured":"Sode M, Thagaard J, Eriksen JO, Laenkholm A-V (2023) Digital image analysis and assisted reading of the HER2 score display reduced concordance: pitfalls in the categorisation of HER2-low breast cancer. Histopathology 82:912\u2013924. https:\/\/doi.org\/10.1111\/his.14877","journal-title":"Histopathology"},{"key":"4425_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/diagnostics13010168","volume":"13","author":"C Palm","year":"2023","unstructured":"Palm C, Connolly CE, Masser R et al (2023) Determining HER2 status by artificial intelligence: an investigation of primary, metastatic, and HER2 low breast tumors. Diagnostics (Basel) 13:168. https:\/\/doi.org\/10.3390\/diagnostics13010168","journal-title":"Diagnostics (Basel)"},{"key":"4425_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100944","author":"B McKelvey","year":"2026","unstructured":"McKelvey B, Torres-Saavedra PA, Li J et al (2026) Agreement across 10 artificial intelligence models in assessing human epidermal growth factor receptor 2 (HER2) expression in breast cancer whole-slide images. Mod Pathol. https:\/\/doi.org\/10.1016\/j.modpat.2025.100944","journal-title":"Mod Pathol"},{"key":"4425_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2021.12.022","volume":"163","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Gandini S, Nicol\u00f2 E et al (2022) Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer 163:35\u201343. https:\/\/doi.org\/10.1016\/j.ejca.2021.12.022","journal-title":"Eur J Cancer"},{"key":"4425_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00741-y","volume":"11","author":"Y Bar","year":"2025","unstructured":"Bar Y, Fell G, Dedeoglu A et al (2025) Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies. NPJ Breast Cancer 11:27. https:\/\/doi.org\/10.1038\/s41523-025-00741-y","journal-title":"NPJ Breast Cancer"},{"key":"4425_CR35","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.ccell.2025.03.020","volume":"43","author":"S Loi","year":"2025","unstructured":"Loi S, Salgado R (2025) AI-driven biomarkers for antibody-drug conjugates. Cancer Cell 43:1000\u20131002. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.020","journal-title":"Cancer Cell"},{"key":"4425_CR36","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","volume":"43","author":"D Ma","year":"2025","unstructured":"Ma D, Dai L-J, Wu X-R et al (2025) Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell 43:1061-1075.e7. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.017","journal-title":"Cancer Cell"},{"key":"4425_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43324-w","volume":"14","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Gupta H, Hughes ME et al (2023) Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nat Commun 14:7496. https:\/\/doi.org\/10.1038\/s41467-023-43324-w","journal-title":"Nat Commun"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04425-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:10:29Z","timestamp":1772694629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04425-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4425"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04425-1","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures implemented in this study complied with the ethical standards of the institutional and national research committees and the Declaration of Helsinki. Retrospective human samples were collected and managed by a Biological Resources Center declared (DC-033-00059) and approved (AC-2008-700) by the competent authorities. All patients included in the study were fully anonymized. This work was supported and approved by the Montpellier Cancer Institute Val d\u2019Aurelle, Montpellier, France (ICM-CORT-2024-28).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"S\u00e9verine Guiu declares the following conflicts of interest: boards\/oral presentation: AstraZeneca; travel: Novartis, Pfizer; financial support to research projects (institutional grants): Pfizer, Lilly, AstraZeneca. William Jacot reports grants, personal fees, and non-financial support from AstraZeneca, grants and personal fees from Daiichi Sankyo, personal fees and non-financial support from Eisai, personal fees and non-financial support from Novartis, personal fees and non-financial support from Roche, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Eli Lilly, personal fees from MSD, personal fees from BMS, personal fees and non-financial support from Chugai, personal fees from Seagen, and personal fees and non-financial support from Gilead outside the submitted work. All the other authors did not receive support from any organization relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}